Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
We propose an eight-week, double-blind, placebo-controlled trial of rosiglitazone in
schizophrenia subjects treated with clozapine using Bergman's Minimal Model (MINMOD)
intravenous glucose tolerance test. Bergman's Minimal Model analysis with frequent sampled
intravenous glucose tolerance test (FSIVGTT) provides a sensitive and reliable method to
measure glucose effectiveness, insulin secretion and insulin sensitivity. The MINMOD
determines the relationship between insulin sensitivity, insulin secretion and the degree of
obesity and can be used to study drug effects upon these variables.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
National Alliance for Research on Schizophrenia and Depression Stanley Medical Research Institute